BIOMARK RECEIVES $825K GRANT TO DEVELOP ITS LIQUID BIOPSY ASSAY FOR LUNG CANCER SCREENING
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) received funding to develop an early-stage lung cancer screening assay using BioMark’s proprietary liquid biopsy platform. The total sponsored research grant is about […]
BIOMARK REÇOIT UNE SUBVENTION DE 825 K $ POUR DÉVELOPPER SON TEST DE BIOPSIE LIQUIDE POUR LE DÉPISTAGE DU CANCER DU POUMON
Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) est heureuse d’annoncer aujourd’hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. (“BDS”) a reçu un financement pour le développement d’un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie […]
BIOMARK ANNOUNCES CHANGE OF AUDITOR
Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announces that it has changed its auditors from Manning Elliott LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors […]
BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC
Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy […]
BIOMARK ANNOUNCES EXERCISE OF WARRANTS AND GAIN DTC ELIGIBILITY FOR ITS COMMON SHARES
Vancouver, British Columbia – (April 21, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company’s private placement of units completed in April 2019, with the warrant […]
BIOMARK’S COLLABORATOR RECEIVES FUNDING TO VALIDATE ITS BIOMARKER PANEL FOR THE EARLY DETECTION OF LUNG CANCER
Vancouver, British Columbia – (March 16, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes […]
BIOMARK GRANTS OPTIONS
Vancouver, British Columbia – (March 2, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has granted 2,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each […]
BIOMARK AND PHYTRONIX TECHNOLOGIES INC. ENTER INTO A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT
Vancouver, British Columbia – (February 16, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. (“Phytronix”) to advance the development of BioMark’s early lung cancer screening applications […]
BIOMARK DIAGNOSTICS TARGETS RESPONSE TO TREATMENT APPLICATION WITH ITS LIQUID BIOPSY PLATFORM
Vancouver, British Columbia – (February 8, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer – a Pilot Study” has been published in the peer-reviewed journal Future Science OA. Rashid A. Bux, […]
BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES
Vancouver, British Columbia – (December 7th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that it has retained Questrade, Inc. (“Questrade”) to provide market-making services in accordance with CSE guidelines. The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either […]
